Literature DB >> 23446490

In vitro synergistic activity of diketopiperazines alone and in combination with amphotericin B or clotrimazole against Candida albicans.

S Nishanth Kumar1, Bala Nambisan, C Mohandas, A Sundaresan.   

Abstract

The synergistic anticandidal activity of three diketopiperazines [cyclo-(L-Pro-L-Leu) (1), cyclo-(D-Pro-L-Leu) (2), and cyclo-(D-Pro-L-Tyr) (3)] purified from a Bacillus sp. N strain associated with entomopathogenic nematode Rhabditis (Oscheius) in combination with amphotericin B and clotrimazole was investigated using the macrodilution method. The minimum inhibitory concentration and minimum fungicidal concentration of the diketopiperazines was compared with that of the standard antibiotics. The synergistic anticandidal activities of diketopiperazines with amphotericin B or clotrimazole were assessed using the checkerboard and time-kill methods. The results of the present study showed that the combined effects of diketopiperazines with amphotericin B or clotrimazole predominantly recorded synergistic (<0.5). Time-kill study showed that the growth of the Candida was completely attenuated after 12-24 h of treatment with 50:50 ratios of diketopiperazines and antibiotics. These results suggest that diketopiperazines combined with antibiotics may be microbiologically beneficial and not antagonistic. These findings have potential implications in delaying the development of resistance as the anticandidal effect is achieved with lower concentrations of both drugs (diketopiperazines and antibiotics). The cytotoxicity of diketopiperazines was also tested against two normal human cell lines (L231 lung epithelial and FS normal fibroblast) and no cytotoxicity was recorded for diketopiperazines up to 200 μg/mL. The in vitro synergistic activity of diketopiperazines with antibiotics against Candida albicans is reported here for the first time.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23446490     DOI: 10.1007/s12223-013-0234-x

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN: 0015-5632            Impact factor:   2.099


  38 in total

Review 1.  New approaches to optimizing antimicrobial therapy in patients with cystic fibrosis.

Authors:  P M Beringer
Journal:  Curr Opin Pulm Med       Date:  1999-11       Impact factor: 3.155

2.  Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy.

Authors:  Francesco Barchiesi; Monia Maracci; Brunella Radi; Daniela Arzeni; Isabella Baldassarri; Andrea Giacometti; Giorgio Scalise
Journal:  J Antimicrob Chemother       Date:  2002-12       Impact factor: 5.790

Review 3.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

Review 4.  Molecular biology of the symbiotic-pathogenic bacteria Xenorhabdus spp. and Photorhabdus spp.

Authors:  S Forst; K Nealson
Journal:  Microbiol Rev       Date:  1996-03

5.  Nosocomial bloodstream infections in United States hospitals: a three-year analysis.

Authors:  M B Edmond; S E Wallace; D K McClish; M A Pfaller; R N Jones; R P Wenzel
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

6.  Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.

Authors:  Matthew Morrell; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

7.  Inhibition of NF-kappaB sensitizes A431 cells to epidermal growth factor-induced apoptosis, whereas its activation by ectopic expression of RelA confers resistance.

Authors:  Ruby John Anto; Manickam Venkatraman; Devarajan Karunagaran
Journal:  J Biol Chem       Date:  2003-04-24       Impact factor: 5.157

8.  Lactobacillus plantarum MiLAB 393 produces the antifungal cyclic dipeptides cyclo(L-Phe-L-Pro) and cyclo(L-Phe-trans-4-OH-L-Pro) and 3-phenyllactic acid.

Authors:  Katrin Ström; Jörgen Sjögren; Anders Broberg; Johan Schnürer
Journal:  Appl Environ Microbiol       Date:  2002-09       Impact factor: 4.792

Review 9.  Bioactive cyclic dipeptides.

Authors:  C Prasad
Journal:  Peptides       Date:  1995       Impact factor: 3.750

10.  A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

Authors:  John H Rex; Peter G Pappas; Adolf W Karchmer; Jack Sobel; John E Edwards; Susan Hadley; Corstiaan Brass; Jose A Vazquez; Stanley W Chapman; Harold W Horowitz; Marcus Zervos; David McKinsey; Jeannette Lee; Timothy Babinchak; Robert W Bradsher; John D Cleary; David M Cohen; Larry Danziger; Mitchell Goldman; Jesse Goodman; Eileen Hilton; Newton E Hyslop; Daniel H Kett; Jon Lutz; Robert H Rubin; W Michael Scheld; Mindy Schuster; Bryan Simmons; David K Stein; Ronald G Washburn; Linda Mautner; Teng-Chiao Chu; Helene Panzer; Rebecca B Rosenstein; Jenia Booth
Journal:  Clin Infect Dis       Date:  2003-05-08       Impact factor: 9.079

View more
  3 in total

1.  Antibacterial Activity of Two Metabolites Isolated From Endophytic Bacteria Bacillus velezensis Ea73 in Ageratina adenophora.

Authors:  Zhihua Ren; Lei Xie; Samuel Kumi Okyere; Juan Wen; Yinan Ran; Xiang Nong; Yanchun Hu
Journal:  Front Microbiol       Date:  2022-05-06       Impact factor: 6.064

2.  Purification and synergistic antibacterial activity of arginine derived cyclic dipeptides, from Achromobacter sp. associated with a rhabditid entomopathogenic nematode against major clinically relevant biofilm forming wound bacteria.

Authors:  Indira Deepa; Sasidharan N Kumar; Ravikumar S Sreerag; Vishnu S Nath; Chellapan Mohandas
Journal:  Front Microbiol       Date:  2015-08-25       Impact factor: 5.640

Review 3.  Techniques for the Assessment of In Vitro and In Vivo Antifungal Combinations.

Authors:  Anne-Laure Bidaud; Patrick Schwarz; Guillaume Herbreteau; Eric Dannaoui
Journal:  J Fungi (Basel)       Date:  2021-02-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.